GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?

Investor logo

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

HORSKÁ Kateřina RUDÁ Jana SKREDE Silje

Year of publication 2022
Type Article in Periodical
Magazine / Source TRENDS IN ENDOCRINOLOGY AND METABOLISM
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.sciencedirect.com/science/article/pii/S1043276022001229?via%3Dihub
Doi http://dx.doi.org/10.1016/j.tem.2022.06.005
Keywords antipsychotic; metabolic adverse effects; GLP-1 receptor agonist; pro-cognitive; schizophrenia
Description Antipsychotics (APDs) represent a core treatment for severe mental disorders (SMEs). Providing symptomatic relief, APDs do not exert therapeutic effects on another clinically significant domain of serious mental disorders, cognitive impair-ment. Moreover, adverse metabolic effects (diabetes, weight gain, dyslipidemia, and increased cardiovascular risk) are common during treatment with APDs. Among pharmacological candidates reversing APD-induced metabolic adverse effects, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs), approved for both diabetes and recently for obesity treatment, stand out due to their favorable effects on peripheral metabolic parameters. Interestingly, GLP-1 RAs are also proposed to have pro-cognitive effects. Particularly in terms of dual therapeutic mechanisms potentially improving both central nervous system (CNS) deficits and metabolic burden, GLP-1 RAs open a new perspective and assume a clinically advantageous position.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.